SPONSOR
SCRI Development Innovations, LLC
Total Trials
2
Recruiting
2
Phases
Phase 2
NCT07011576 Phase 2
Recruiting
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
Colon Cancer
NCT05748834 Phase 2
Recruiting
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Breast Cancer